VitaOptix Asia Pacific Business Expansion and Otica Brand Launch

Strategic Expansion with AI and Spectral Technology

Shanghai, China, 15th Jan 2026 – Global AI spectral skin technology company VitaOptix (UK) today announced two strategic milestones: the launch of its Asia-Pacific R&D Center in Shanghai, China, and the opening of its Bangkok Market Operations Center in Thailand. These developments mark the company’s entry into the Southeast Asian market.
Alongside this expansion, VitaOptix introduced Otica, a specialized intimate health brand. The brand is scheduled to introduce an AI Intimate Detection System and Pelvic Floor Magnetic Therapy Solution to the Thai market to provide standardized women’s health management options.

Infrastructure Development: China R&D Center and Thailand Hub
The Shanghai base serves as the first overseas R&D center for VitaOptix, focusing on the development of AI spectral algorithms and clinical validation systems. The facility is staffed by a 30-member interdisciplinary team, including optical engineers, biologists, and AI specialists. Dr. Chen, Head of the Center, stated: “We are adapting the AI spectral technology from our skin analyzers to gynecological detection scenarios to enhance diagnostic precision in the intimate health sector.” The development of the next-generation AI multimodal detection robot, Intima AI Robot, is led by this center and is scheduled for release in 2026.
Based in Bangkok, the Thailand Market Operations Center provides localized services and plans to collaborate with medical aesthetics institutions. Dr. Stefan Müller, Founder of VitaOptix, stated: “Thailand’s annual medical tourism revenue exceeds $7 billion. We chose to establish a foothold here due to its mature private healthcare network and open policy environment, making it a strategic pivot to tap into the 600-million-person ASEAN market.”

Otica Brand: Integration of Technology in Health Management
Utilizing technical resources from the China R&D Center, VitaOptix launched the Otica brand, applying AI spectral technology to female health management. The brand’s technology suite focuses on non-invasive assessment and rehabilitation support.
The product line includes an AI Intimate Detection Device that utilizes multi-spectral imaging and AI deep learning for the assessment of female health indicators. For rehabilitation, the brand offers a Pelvic Floor Magnetic Therapy Device, which employs targeted electromagnetic pulses and biofeedback to support pelvic organ recovery. Additionally, Otica provides health care solutions combining EMS and SPA regulation therapy for tissue management and care.
“Traditional gynecological exams often rely on invasive methods, whereas Otica’s AI spectral detection completes an assessment in 3 minutes,” said Dr. Chen.

Market Context: Health Management Trends
This expansion represents the transition of VitaOptix from skin detection to deep tissue health management. Market observations from Frost & Sullivan indicate that the intimate health sector is experiencing growth exceeding 25% annually. The application of AI spectral technology establishes a technical barrier for the Otica brand, while the establishment of the Thailand center is expected to facilitate procurement processes for beauty institutions across Southeast Asia.
 

Media Contact

Organization: Shanghai VitaOptix Technology Co., LTD.

Contact Person: Stefan

Website: https://www.vitaoptix.com/

Email: Send Email

City: Shanghai

Country:China

Release id:40195

Disclaimer: This content includes references to health-related technologies and is provided for general informational purposes only. It does not constitute medical, diagnostic, or therapeutic advice, nor does it make claims regarding clinical outcomes or effectiveness.

The post VitaOptix Asia Pacific Business Expansion and Otica Brand Launch appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Michigan News journalist was involved in the writing and production of this article.